Below is the list of clinical trials currently available at the Cancer Institute of Florida Hospital Memorial Medical Center.
For any questions or to learn if you qualify for a trial, please contact our clinical trial research coordinator at (386) 231-4023.
Clinical trials with Florida Cancer Specialists can be found at www.flcancer.com/trialnavigator
Breast Cancer Studies
Alliance/NCI A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer - NCT02750826 (FHMMC, Flagler, FISH, Deland)
#311-06-EP Breast Cancer Collaborative Registry Trial (BCCR): A Breast Cancer Information Registry for Participants with Breast Cancer or Characteristics of Hereditary Breast Cancer. (FHMMC, Flagler, FISH, Deland) NCT00666731
BRE 257/FCS A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer-NCT02370238 (FHMMC/Daytona)
BRE 267/FCS Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)- NCT02437318 (FHMMC/Daytona)
Lung Cancer Studies
LUN 298/ GO29437: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin +Paclitaxel or MPDL3280A In Combination with Carboplatin + Nab-Paclitaxel Versus Carboplatin + Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NCT02367794)
LUN 299/GO29537: A Phase III, Multicenter, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Nab-Paclitaxel For Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NCT02367781)
LUN 308/ GO29527: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3280A (Atezolizumab, Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Chemotherapy in Patients With Lung Cancer (NCT02486718)
https://clinicaltrials.gov/ct2/show/NCT02486718 (coming soon)
Amgen 20120139: "A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with
Melanoma Who Previously Received Talimogene Laherparepvec." NCT02173171 (FHMMC)
MEL 41/FCS: A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma NCT01656642 (coming soon FHMMC/Daytona Cancer Ctr.)
A221101 “A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodfinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma."
GYN 60/FCS: A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) NCT02580058 (FHMMC/Daytona Cancer Ctr.)